Alzamend Neuro is trading 5.3% down at $1.26 in after-hours trading, giving back a portion of its regular-session gains as the rally sparked by its annual report loses steam.
- The stock initially climbed after the company's annual report outlined an $8.8 million loss, a funding shortfall, and updated timelines for its clinical trials.
- The move lower after the closing bell suggests profit-taking and normal market volatility, as no new company-specific news has been released to justify the reversal.